政府調達令和8年1月13日
筑波大学附属病院における医薬品等の一般競争入札公告
掲載日
令和8年1月13日
号種
政府調達
原文ページ
p.98
出典：官報発行サイトの掲載情報を加工しています。AI 抽出や OCR に誤りが含まれる可能性があるため、 重要な確認は公式原文を基準にしてください。
抽出された基本情報
本文と原文の対照
まず左側の本文を読み、必要な箇所だけ原文ページで確認できる構成です。
← 同日の官報に戻る
原文対照の表示オプション
筑波大学附属病院における医薬品等の一般競争入札公告
令和8年1月13日|p.98
本文はAI抽出です。左の段落を選ぶと、右側の官報原文画像で該当箇所を照合できます。
5 Summary
(1) Official in charge of disbursement of the
procuring entity : Yuji Hiramatsu, The Ob-
ligating Officer Director, University of Tsu-
kuba Hospital
(2) Classification of the products to be pro-
cured : 4
(3) Nature and quantity of the products to be
purchased :
A Onasemnogene abeparvovec about 1
set
B Ravulizumab (Genetical Recombina-
tion) 300mg/3mL 1vial/case about 900
cases
C Ravulizumab (Genetical Recombina-
tion) 1100mg/11mL 1vial/case about
200 cases
D Crovalimab (Genetical Recombination)
340mg/2mL 1vial/case about 180 cases
E Axicabtagene ciloleucel about 10 sets
F Idecabtagene vicleucel about 10 sets
G Pertuzumab (Genetical Recombina-
tion) Trastuzumab (Genetical Recom-
bination) Vorhyaluronidase Alfa (Ge-
netical Recombination) 10mL 1vial/case
about 680 cases
H Satralizumab (Genetical Recombina-
tion) 120mg/1mL 1syringe/case about
130 cases
I Eculizumab (Genetical Recombination)
300mg/30mL 1vial/case about 230
cases
J Sutimlimab (Genetical Recombination)
1100mg/22mL 1vial/case about 430
cases
K Polatuzumab Vedotin (Genetical Re-
combination) 30mg 1vial/case about 400
cases
L Garadacimab (Genetical Recombina-
tion) 200mg 1kit/case about 30 cases
M Efgartigimod Alfa (Genetical Re-
combination) Vorhyaluronidase Alfa
(Genetical Recombination) 5.6mL 1vial/
case about 150 cases
N Tisagenlecleucel about 5 sets
O Mosunetuzumab (Genetical Recom-
bination) 30mg/30mL 1vial/case about
30 cases
P Glucarpidase (Genetical Recombina-
tion) 1000U 1vial/case about 10 cases
Q Pertuzumab (Genetical Recombina-
tion) Trastuzumab (Genetical Recom-
bination) Vorhyaluronidase Alfa (Ge-
netical Recombination) 15mL 1vial/case
about 60 cases
R Risdiplam 5mg 7tablets/case about 60
cases
S Teduglutide (Genetical Recombina-
tion) 3.8mg 1vial/case about 330 cases
T Polatuzumab Vedotin (Genetical Re-
combination) 140mg 1vial/case about 20
cases
U Cetuximab Sarotalocan Sodium (Ge-
netical Recombination) 250mg/50mL
1vial/case about 20 cases
V Nusinersen Sodium 12mg/5mL
1vial/case about 5 cases
W Andexanet Alfa (Genetical Recom-
bination) 200mg 1vial/case about 50
cases
(4) Delivery period : From 1 April, 2026 th-
rough 31 March, 2027
(5) Delivery place: The University of Tsu-
kuba Hospital
(6) Qualifications for participating in the
tendering procedures : Suppliers eligible for
participating in the proposed tender are
those who shall :
A not come under Article 46 and 47 of the
Regulation concerning the Contract for
University of Tsukuba Furthermore, mi-
nors, Person under Conservatorship or
Person under Assistance that obtained
the consent necessary for concluding a
contract may be applicable under cases
of special reasons within the said clause,
B have the Grade A, Grade B or Grade C
qualification during fiscal 2026 in the
Kanto Koshinetsu area in sales of prod-
uct for participating in tenders by Single
qualification for every ministry and agen-
cy,
C prove to have obtained either the first-
class license or the third-class license for
selling drugs in accordance with the Law
on Securing Quality, Efficacy and Safety
of Products including Pharmaceuticals
and Medical Devices,
D prove to have the ability to deliver the
products, required by this notice, on the
date and to the place specified by The
Obligating Officer,
E meet the qualification requirements
which The Obligating Officer Director
may specify in accordance with Article
49 of the Regulation,
F not be currently under a suspension of
business order as instructed by The Ob-
ligating Officer.
(7) Time limit of tender : 12:00 12 March,
2026
(8) Contact point for the notice: Yuki
Murasawa, Division of Accounting, Depart-
ment of University Hospital Management,
University of Tsukuba, 2-1-1 Amakubo
Tsukuba-shi 305-8576 Japan, TEL 029-
853-3543
(9) Please be noted that if it is indicated that
environmental conditions relating to the
procurement are laid down in its tender do-
cuments.
読み込み中...
テキスト領域
選択中
非公開 (PII)